Merck to pony up $625M plus Keytruda royalties to settle BMS, Ono patent fight

Merck & Co. will pony up $625 million plus royalties on its blockbuster PD-1 cancer drug Keytruda to settle up its patent dispute with Opdivo-maker Bristol-Myers Squibb and its development partner, Ono.